U.S., Oct. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07880106) titled 'Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer' on Oct. 11.
Brief Summary: This single-center cohort study integrates humoral immune response profiling (Phage ImmunoPrecipitation Sequencing, PhIP-seq) with circulating cell-free DNA (cfDNA) genomic and epigenomic features, exosome transcriptomics, and plasma metabolomics to discover and validate liquid-biopsy biomarkers of treatment response in breast cancer.
The study comprises four cohorts: (1) a retrospective pan-cancer cohort of approximately 1,000 patients with solid malignant tumor, using archived residual serum/plasma to construct a pan-cance...